Detection and quantitation of circulating tumor cell dynamics by bioluminescence imaging in an orthotopic mammary carcinoma model

• Published in: PloS one 2014-09, Vol.9 (9), p.e105079-e105079
• Main Authors: Sasportas, Laura Sarah, Hori, Sharon Seiko, Pratx, Guillem, Gambhir, Sanjiv Sam
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Biology and Life Sciences; Bioluminescence; Blood; Breast cancer; Cancer; Carcinoma; Cell Line, Tumor; Cloning; Disease Progression; Dynamic tests; Dynamics; Enumeration; Female; Hemolysis; Identification; Imaging; Luminescent Measurements - methods; Lung Neoplasms - secondary; Lungs; Mammary gland; Mammary Neoplasms, Experimental - blood; Mammary Neoplasms, Experimental - pathology; Mammary Neoplasms, Experimental - secondary; Medicine and Health Sciences; Metastases; Metastasis; Mice; Mice, Nude; Neoplasm Invasiveness - pathology; Neoplastic Cells, Circulating - pathology; Patients; Physical Sciences; Quantitation; Research and Analysis Methods; Tumor cells
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0105079

Circulating tumor cells (CTCs) have been detected in the bloodstream of both early-stage and advanced cancer patients. However, very little is know about the dynamics of CTCs during cancer progression and the clinical relevance of longitudinal CTC enumeration. To address this, we developed a simple bioluminescence imaging assay to detect CTCs in mouse models of metastasis. In a 4T1 orthotopic metastatic mammary carcinoma mouse model, we demonstrated that this quantitative method offers sensitivity down to 2 CTCs in 0.1-1mL blood samples and high specificity for CTCs originating from the primary tumor, independently of their epithelial status. In this model, we simultaneously monitored blood CTC dynamics, primary tumor growth, and lung metastasis progression over the course of 24 days. Early in tumor development, we observed low numbers of CTCs in blood samples (10-15 cells/100 µL) and demonstrated that CTC dynamics correlate with viable primary tumor growth. To our knowledge, these data represent the first reported use of bioluminescence imaging to detect CTCs and quantify their dynamics in any cancer mouse model. This new assay is opening the door to the study of CTC dynamics in a variety of animal models. These studies may inform clinical decision on the appropriate timing of blood sampling and value of longitudinal CTC enumeration in cancer patients.